The narrative highlights the importance of creating intentional spaces of silence and mindfulness amidst the chaos of chronic ...

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people ...

Preclinical AML studies showed palbociclib plus venetoclax produced stronger, more durable anti‑leukemia activity than venetoclax alone and may overcome resistance.

Donna Ford's leukemia diagnosis came after a minor fall. Her treatment included chemo and a revolution procedure called meningeal artery embolization.

BAKERSFIELD, Calif. (KERO) — Taking a crisis and responding with kindness — that’s the mission behind the nonprofit Helping One Woman (HOW). This month, that “one woman” is actually a 12-year-old girl ...

The 36-month PFS rate for patients with del (17p) and/or TP53 mutation was 87% and for patients without del (17p) and TP53 mutation was 89%. The safety profile of BRUKINSA plus venetoclax was ...

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia overcome resistance to one of the most common ...

Chicago-based Ann & Robert H. Lurie Children’s Hospital has established an advanced leukemia clinical and research program to expand access to clinical trials and novel therapies for patients in the ...

Researchers at Oregon Health and Science University (OHSU) have discovered a promising new drug combination that could ...